Literature DB >> 30623865

Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations.

Athanasios Dellis1, Flora Zagouri2, Michalis Liontos3, Dionysios Mitropoulos4, Aristotelis Bamias2, Athanasios G Papatsoris5.   

Abstract

The therapeutic landscape of advanced prostate cancer is continuously changing under the light of new available treatment options and the improved understanding of the molecular characteristics of the disease. The lack of high quality evidence regarding the sequencing of these treatments along with the earlier implementation of these therapeutic approaches during the course of the disease have created issues of dispute regarding the optimal treatment of patients with advanced prostate cancer. Therefore, we conducted a systematic review of the existing guidelines and recent randomized trials not included in these guidelines, and present a comprehensive analysis of the available treatment options in each of the stages of advanced prostate cancer, as well as the supportive treatments available for these patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Guidelines; Prostate cancer

Mesh:

Year:  2018        PMID: 30623865     DOI: 10.1016/j.ctrv.2018.11.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  6 in total

Review 1.  Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.

Authors:  Reka Varnai; Leena M Koskinen; Laura E Mäntylä; Istvan Szabo; Liesel M FitzGerald; Csilla Sipeky
Journal:  Genes (Basel)       Date:  2019-08-08       Impact factor: 4.096

2.  Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy.

Authors:  Cristina Buigues; Rut Navarro-Martínez; Vanessa Sánchez-Martínez; María Serrano-Carrascosa; José Rubio-Briones; Omar Cauli
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

3.  Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.

Authors:  Ayşe Demirci; Cemil Bilir; Burcu Gülbağcı; İlhan Hacıbekiroğlu; İbrahim V Bayoğlu; İrem Bilgetekin; Sinan Koca; Havva Y Çınkır; Nadiye Akdeniz; Deniz Gül; Ceyhun Varım; Umut Demirci; Berna Öksüzoğlu
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

4.  Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.

Authors:  Ting-Miao Wu; Ji-Bin Liu; Yu Liu; Yi Shi; Wen Li; Gao-Ren Wang; Yu-Shui Ma; Da Fu
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

5.  What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer.

Authors:  Emma Dunlop; Aimee Ferguson; Tanja Mueller; Kelly Baillie; Julie Clarke; Jennifer Laskey; Amanj Kurdi; Olivia Wu; Rob Jones; Hilary Glen; Marion Bennie
Journal:  Support Care Cancer       Date:  2021-12-08       Impact factor: 3.359

6.  Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.

Authors:  Ding-Fang Zhang; Zhi-Chun Yang; Jian-Qiang Chen; Xiang-Xiang Jin; Yin-da Qiu; Xiao-Jing Chen; Hong-Yi Shi; Zhi-Guo Liu; Min-Shan Wang; Guang Liang; Xiao-Hui Zheng
Journal:  BMC Complement Med Ther       Date:  2021-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.